Embic Corporation develops digital cognitive biomarkers, which can resolve urgent problems in multiple healthcare channels, including the pre-symptomatic identification of Alzheimer’s Disease. To generate these biomarkers, Embic has deployed a brief cognitive test battery on an electronic platform enabling efficient test administration, automatic data collection, and real-time delivery of results generated by proprietary scoring algorithms. This battery has been administered nearly two million times by its clients, and the database of responses comprises a growing normative dataset for ongoing R&D. From this dataset, Embic has recently developed proprietary algorithms for quantifying the unobservable cognitive processes of information encoding and retrieval. These new digital biomarkers will have a profound impact on clinical care, diagnostics, and the field of Alzheimer’s research. Embic’s analytic algorithms have been validated through medical journal publications, NIH grants, and industry adoption.